ArticleSchizophrenia bulletin open2026
Are Depot Antipsychotics Ever Self-Tapering? Exploring the Discontinuation of Long-Acting Injectable Psychosis Drugs and Those With Delayed Onset Through In Silico Modelling.
Article in Schizophrenia bulletin open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Hypothesis: Reducing and stopping antipsychotic medications can have longer-term positive outcomes for some patients. Despite common wisdom, abrupt discontinuation of several long-acting injectable (LAI) antipsychotic drugs results in rapid D Study Design: Pharmacokinetic data were collated for 6 LAI antipsychotic forms (aripiprazole lauroxil, olanzapine pamoate, paliperidone palmitate 1-, 3-, and 6-monthly, and risperidone microspheres). Fifty-two studies comprising 6146 patients were included. In silico modelling was completed to predict RODOC from abrupt discontinuation. We used RODOC thresholds of 5 percentage-point (pp) difference per month as a proxy measure to theoretically estimate the likelihood of withdrawal effects emerging, with sensitivity analyses for 2.5 and 10 pp/month. Study Results: Abrupt cessation of LAIs is likely to exceed 5 pp/month RODOC for all examined LAIs except paliperidone palmitate 6-monthly. Peak rates of D Conclusions: Almost all LAI antipsychotic medications could theoretically cause withdrawal effects in most patients if abruptly discontinued without oral supplementation. However, abrupt discontinuation of longer-acting paliperidone palmitate could theoretically be successful for some patients. Prescribers must collaborate with patients when devising tapering regimens to ensure schedules are personalized and responsive to individual experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.